Transcend Capital Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Transcend Capital Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,000	Closed	-$306K	–	516
2023 Q2	$306K	Hold	3,000	–	–	0.03%	366
2023 Q1	$273K	Buy	+3,000	New	+$176K	0.03%	380
2021 Q4	–	Sell	-5,000	Closed	-$485K	–	523
2021 Q3	$485K	Buy	+5,000	New	+$586K	0.04%	305
2021 Q2	–	Sell	-5,650	Closed	-$564K	–	453
2021 Q1	$564K	Buy	5,650 +250	+5%	+$29.2K	0.07%	233
2020 Q4	$668K	Buy	+5,400	New	+$710K	0.09%	205

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Transcend Capital Advisors's RETA Position: Q3 2023 in Review

Transcend Capital Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 3,000 shares — an estimated $306K sold.

Transcend Capital Advisors first reported a position in RETA in Q4 2020 and held it in 5 quarters. The position peaked at $668K in Q4 2020. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Transcend Capital Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Transcend Capital Advisors sold 3,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $306K.
Transcend Capital Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2020 and held it in 5 quarters.
Transcend Capital Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $668K in Q4 2020.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Transcend Capital Advisors's 13F filing for Q3 2023, filed 31 Oct 2023.